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Despite established clinical utilisation, there is an increasing need for safer, more inert
gadolinium-based contrast agents, and for chelators that react rapidly with radiometals. Here
we report the syntheses of a series of chiral DOTA chelators and their corresponding metal
complexes and reveal properties that transcend the parent DOTA compound. We incorpo-
rated symmetrical chiral substituents around the tetraaza ring, imparting enhanced rigidity to
the DOTA cavity, enabling control over the range of stereoisomers of the lanthanide com-
plexes. The Gd chiral DOTA complexes are shown to be orders of magnitude more inert to
Gd release than [GdDOTA]−. These compounds also exhibit very-fast water exchange rates
in an optimal range for high ﬁeld imaging. Radiolabeling studies with (Cu-64/Lu-177) also
demonstrate faster labelling properties. These chiral DOTA chelators are alternative general
platforms for the development of stable, high relaxivity contrast agents, and for radiometal
complexes used for imaging and/or therapy.
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Gadolinium-based contrast agents (GBCAs) are commonlyused for diagnosis and monitoring of many diseases. Over30 million doses of GBCAs are administered worldwide
annually1. However, since 2006, it was recognised that free
gadolinium ions are associated with a rare, but devastating toxi-
city called nephrogenic systemic ﬁbrosis (NSF) in patients with
renal impairment2, 3 leading to a contraindication of Gd-DTPA,
Gd-DTPA-BMA and Gd-DTPA-BMEA in the patient popula-
tion4. More recently, it has been found that gadolinium (Gd) can
accumulate in the brains of patients, even those with normal renal
function5–7. The European Medicines Agency (EMA) has
recommended to restrict the clinical use of some acyclic (linear)
Gd agents and suspend the authorisations of others in order to
prevent any risks that could potentially be associated with Gd
brain deposition.
GBCAs can be classiﬁed into macrocyclic and acyclic agents
based on the nature of the chelating moiety. Association of Gd
with NSF and brain deposition is higher for the acyclic Gd(III)
chelates, which are more kinetically labile than the macrocyclic
chelates8. The Food and Drug Administration also announced
that additional text explaining that linear GBCAs carry a greater
risk than macrocyclic agents will be added to the label. It is well-
known that free Gd is toxic; the ionic radius of Gd3+ (108 pm) is
close to that of Ca2+ (114 pm) causing Gd3+ to act as a potent
antagonist of many types of voltage-gated calcium channels at
very-low concentrations9. [GdDOTA]−, with the scaffold of
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
has the highest thermodynamic and kinetic stability among the
clinically used GBCAs10. However, several animal studies showed
Gd deposition was also detected in brains following [GdDOTA]−
administration11–13, so the development of safer, more inert
GBCAs is needed.
High relaxivity is also critical for MRI contrast agents. A key
molecular factor for relaxivity is the water exchange rate at the Gd
ion. [GdDOTA]− and other GBCAs have water exchange rates
that are too slow for optimal relaxivity14. In addition to providing
a stable complex with respect to Gd release, the ideal chelator should
also enable an optimal water exchange rate in the 108–109 s−1
range15–17.
Beyond MR contrast agents, the DOTA chelator has shown
great utility for binding radiometals like In-111 and Cu-64 for
imaging and Lu-177 and Y-90 for therapy18, 19. Inertness of the
complex with respect to metal release is a key feature here as well.
In addition, mild, rapid labelling conditions are necessary prop-
erties of the chelator, especially when the chelator is conjugated to
a thermally sensitive biomolecule.
Herein, we present the synthesis and structural properties of
chiral DOTA system as a platform for safer and high relaxivity
MR contrast agents, and for rapid radiolabelling with radiometals.
Five chiral DOTAs with various chiral groups are synthesised. No
substitution is performed on the acetate pendant arms in order to
retain the natural chelating properties of the cavity formed from
the eight coordinate points of N(4) and O(4). The chiral sub-
stituents on the opposite side of the metal ion can be used for
targeting or conjugating with other molecules, while allowing the
coordinated water molecules to exchange freely. We ﬁnd that our
complexes have optimal water exchange kinetics and high stabi-
lity that transcends [GdDOTA]− signiﬁcantly, thereby providing
an ideal platform to be merged with various macromolecules or
nanoparticles through multilocus binding or conjugation to
become contrast agents with high relaxivity for clinical diagnosis.
Radiolabelling studies with Cu-64 and Lu-177 also demonstrate
the faster labelling properties of chiral DOTA than DOTA,
making them excellent candidates for use as radiometal chelators.
Pharmacokinetics and biodistribution are readily tuned by the
choice of chiral substituent.
Results
Synthesis of chiral DOTA complexes. Five chiral DOTAs (L1–
L5) with various chiral groups were synthesised (Fig. 1, Supple-
mentary Fig. 1). We hypothesised that the chiral substituents
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Fig. 1 Synthetic procedures of chiral DOTA complexes. The chiral cyclens were synthesised from chiral aziridines followed by the incorporation of
protected acetate arms and subsequent deprotections to give the ﬁnal ligands. (a) TsOH/EtOH, RT (1a); (b) BF3·Et2O/Benzene, reﬂux (1b – 1d), 24 h;
(c) TsOH/ACN, RT (1b, 1e); (d) Pd(OH)2/C, ammonium formate, triﬂuoroethanol, 50–75 °C, 16 h; (e) tert-butyl 2-bromoacetate, K2CO3, dry acetonitrile,
50–60 °C, 16 h; (f) TFA/DCM (1:1), 16 h; (g) 1 M HCl (L2 – L4); (h) LnCl3·6H2O, pH 7.0, 80 °C, 12 h (Ln= Eu(III), Yb(III) and Gd(III)), note for clarity the
counterions are not depicted
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would preorganize the chelator in a conformation favourable for
metal ion binding, thereby increasing chelation kinetics. We
further hypothesised that the chiral substituents would lock the
conformation of the chelator making subsequent dechelation very
slow. The synthesis of the twelve-membered ring of cyclen
(1,4,7,10-tetraazacyclododecane) from an aziridine compound
and the corresponding chiral substituted compounds have been
studied for several decades20. However, literature examples of
chiral cyclens are rare. The two backbones reported (with four
methyl and four hydroxymethyls)21, 22 required very complicated
synthetic procedures, which may be the main reason for their
apparent unpopularity. The method of total synthesis of chiral
cyclen with four 4-methoxybenzyl groups is even more daunt-
ing23. Interestingly, the better studied chiral cyclen compound
(with four ethyl groups)20, 24 has no DOTA derivatives developed.
In our work, we have improved and employed synthetic routes
that simpliﬁes the synthesis and puriﬁcation of chiral cyclens.
The chiral cyclens (2a – 2e) were synthesised from chiral
aziridines (synthesised from natural amino acids), catalysed by
either TsOH or Lewis acid boron triﬂuoride diethyl etherate20–22.
We found that if TsOH is used, changing the solvent from
ethanol to acetonitrile gave higher conversions and isolated yields.
The resulted twelve-membered ring compounds are 4-fold
symmetric with the chiral substituents symmetrically arranged
around the cyclen ring at one side of the plane and the benzyl
groups located on the other side. This was conﬁrmed by both
NMR spectroscopy and X-ray crystallography (Fig. 2, Supple-
mentary Table 1), with all four substituents in the S conﬁguration,
indicating that their absolute conﬁgurations did not change in the
cyclization reactions. To further validate this, we crystallised both
conformations of the enantiomeric 2b from different phenyl ring
solvents. 3a–3e are also 4-fold symmetric, conﬁrmed by 1H and
13C NMR spectroscopy as there is only one set of resonances
while 4a–4e are dissymmetric, as the four bulky tert-butyl acetate
groups contributed to a crowded molecular environment with
little freedom for rearrangement. Yet after removing the tert-butyl
groups by deprotection, L1–L5 were obtained in the form of
either triﬂuoroacetic or hydrochloride salts and became 2-fold
symmetric, with two sets of resonances with a ratio of ~1:1
observed. The respective lanthanide chiral DOTA complexes were
synthesised by mixing the ligands and the metal ions and stirred
at 80 °C for 12 h (pH 7.0). Single crystals of [GdL4]− suitable for
single X-ray diffraction were grown by slow evaporation of a
solution mixture of DMF/H2O 1:10 (v/v). The geometry of
[GdL4]− was found to be TSAP/side (vide infra).
Structural isomerism of chiral DOTA complexes. In aqueous
solution, the ratio of TSAP/SAP isomers of Eu(III) and Yb(III)
complexes in DOTA-like systems can be easily identiﬁed by 1H
NMR as two well-deﬁned sets of six resonances are observed for
the diastereotopic CH2CO and ring NCH2CH2N protons25. For
Gd(III) complexes, although they cannot be analysed by NMR,
their ratios of isomers are expected to be similar to the Eu(III)
because the ionic radius of Gd(III) is very similar to that of Eu
(III). No detectable change in the ratio of isomers was observed in
the 1H NMR spectra of the complexes after storing for 6 months
at room temperature. The 1H NMR spectra of the ﬁve Eu(III)
chiral DOTA complexes are compared in Fig. 3.
It has been established that in solution, the square antipris-
matic (SAP) structure is characterised by a shift to a higher
frequency of the closest of the ring axial protons, while this
resonance is less shifted for the twisted square antiprism (TSAP)
isomer26. The isomer ratio of TSAP/SAP increased from 0.75 for
[EuL1]− to 1.27 for [EuL2]− (in D2O, pD ~7.0). The trend is
more pronounced with [EuL3]− (6.52) and [EuL4]− (13.50) as
their TSAP isomers became more dominant (for these
compounds, a 1:1 mixture of deuterated dimethyl sulfoxide and
deuterium oxide was used to overcome solubility issues). This
variation of isomer ratio accords with the general observations
that increasing the steric demand at the bound metal ion favours
the TSAP geometry25. However, only the SAP isomer was
obtained for [EuL5]−, which may be related to the change in
solvation environment around the butyl chain caused by the polar
terminal amine group; more interestingly, we found these isomers
could be easily isolated by reversed-phase HPLC (except for
[EuL1]−).
To further demonstrate the variation tendency of TSAP/SAP
isomer ratio between these ﬁve ligands, the 1H NMR spectra of
the Yb(III) complexes were studied as well (Fig. 4). The ratio of
TSAP/SAP isomers for [YbL1]− (0.28) and [YbL2]− (0.93) are
relatively lower than the Eu(III) analogues; a minor isomer (0.09)
that was described in [YbL1]− was also observed27. The ratio of
a
b
Fig. 2 Crystal structures of ligands 2b, 2c and complex [GdL4]−. a Crystal structure of 2b (SSSS-λλλλ), 2b (SSSS-δδδδ) and 2c. b Crystal structure of [GdL4]−
from top view, bottom view and side view. Atom labels: C (grey), N (blue), and O (red); H atoms omitted for clarity
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[YbL3]− is similar to [YbL2]− and those for [YbL4]− and
[YbL5]− are consistent with their europium analogues. The
difference in chemical shifts for complexes of L4 is attributed to
the aromatic nature of the benzyl substituent compared to the
alkyl nature of the other compounds.
When the complexation conditions of [EuL2] and [YbL2] were
used for [GdL2]−, the ratio of TSAP/SAP of [GdL2]− was ~1:1 in
the RP-HPLC trace, and the isolated yields for these two isomers
were 46% (ﬁrst peak, SAP) and 48% (second peak, TSAP),
respectively. It is important to note that if the pH was adjusted to
~8.0 right after the addition of ligand, 70% of SAP and 25% of
TSAP isomers would be obtained. This also emphasises that these
two isomers formed are not interconvertible, and that the ratios
of TSAP/SAP are determined by reaction kinetics. This makes it
synthetically practical to control the isomerization by regulating
the complexation conditions. Such phenomena were also
observed with the similar NB-DOTA systems28. Another
interesting discovery described in the Ln-NB-DOTA system is
that the change in size/ionic radii of the Ln(III) metal ion does
not inﬂuence the regioisomeric distribution28, and this also
applies for our complexes (Supplementary Fig. 2).
Stability studies of the chiral DOTA complexes. [EuL2A]− and
[EuL2B]− showed extreme inertness upon heating at 90 °C (pD
7.0 and 6.0, respectively) for 3 days (Supplementary Fig. 3 & 4);
no signs of racemization were observed in [EuL2A]− either after
heating for 3 days at pD 1.0 (Supplementary Fig. 5), nor did the
presence of 1 equivalent of Zn2+ caused any instability (Supple-
mentary Fig. 6).
The kinetic stability of GBCAs, which reﬂects the dissociation
of the Gd ions from its chelate is used to predict the stability
in vivo10. The proton-assisted dissociation and direct attack of the
endogenous ions are regarded as two main pathways that induced
the dissociation of the chelates10. The inertness of our Gd(III)
complexes was maintained up to 7 days after addition of 1000
equivalents of a competitive ligand, DTPA (Supplementary Fig. 7
& 8). Monitored by RP-HPLC29, [GdL2A]− and [GdL2B]− were
also stable under both acidic and alkaline conditions, showing
negligible decomplexation in 1N HNO3 (Supplementary Fig. 9 &
10) and 0.1N NaOH (Supplementary Fig. 11 & 12) over 10 days.
The harshest condition tried was setting the complexes of
[GdL2A]−, [GdL2B]− and [GdDOTA]− in 1N HCl (Fig. 5,
Supplementary Figs. 13 - 15). [GdL2A]− and [GdL2B]− are
much more stable than [GdDOTA]−; there was almost no
decomplexation for [GdL2A]− (SAP isomer), and only minimal
decomplexation for [GdL2B]− (TSAP isomer) after 487 h, while
the half-life of [GdDOTA]− was found to be shorter than 25 h.
Their stability was maintained and no interconversion was
observed with one equivalent of DOTA ligand in 1N HCl
solutions of [GdL2A]− and [GdL2B]− (Supplementary Fig. 16).
The complex [GdL2A]− is also more stable than [GdDOTA]− in
the presence of 100 equivalents of zinc chloride at 50 °C. The half-
life of [GdDOTA]− was ~100 h under this condition, while no
obvious decomplexation was observed for the complex of
[GdL2A]− during the same time (Supplementary Fig. 17 & 18).
So why are the chiral DOTA complexes more stable than
[GdDOTA]−? In general, four different diastereomers are formed
in the process of complexation with DOTA. Two pairs of
enantiomers result in four stereoisomers that could interconvert
in solution by ring-ﬂip or rotation of the acetate pendant arms to
give either monocapped SAP or monocapped TSAP geometries30.
With four substituents, two of these isomeric structures are
restricted and hence are not interconvertible (Fig. 6). The freezing
of the mobility on the macrocyclic ring stabilised the chelate itself,
while the steric hindrance prevents the interaction of the metal
ion and the outer species, such as the transmetallation and acid
catalysed decomplexation. In past studies with one benzyl group
substituted on the macrocyclic ring, the resultant complexes
showed relatively lower stability than [GdDOTA]−. The presence
of corner and side regioisomers is illustrated in complexes of Ln-
NB-DOTA28 and Ln-NB-DOTAM31. There are two pairs of
interconvertible isomers for Ln-NB-DOTA28, however, due to the
symmetry and sterics introduced into our systems, such
regioisomers are eliminated (Fig. 6). This also indicates that the
α-substitutions on the acetate arms (for [LnM4DOTMA]−)32
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caused the structure to be too crowded, and lowered the stability
to yield interconvertible isomers.
Water exchange rates and relaxivity properties. It is evident that
our chiral DOTAs can be selectively controlled to form TSAP/
SAP isomers. This is very important because it is known that the
TSAP/SAP isomers can exhibit very different water exchange
kinetics of the inner-sphere coordinated water. Table 1 shows the
summary of the mean residence time of the water co-ligand at
310K and enthalpy of activation of water exchange for Gd(III)
complexes of L1–L5 and their similar compounds.
All our complexes have very-fast water exchange kinetics
(ﬁtting proﬁles were shown in Supplementary Fig. 19). The water
residence time (τM310K, inverse of exchange rate) of [GdL1]−,
with one coordinated water molecule, was measured to be 13 ±
0.4 ns; it is a weighted average for all the coordination isomers
present. The τM310K values of [GdL2A]− and [Gd(R)L2A]−,
diastereomer and enantiomer of [GdL2]−, respectively, were
measured to be 6.6 ± 0.4 ns and 8.1 ± 0.4 ns; whereas the τM310K
of [GdL2B]− and [Gd(R)L2B]− are 1.1 ± 0.1 ns and 2.9 ± 0.1 ns.
[GdL5]−, exclusively in SAP geometry, has a τM310K of 16 ± 0.8
ns. These very-short water residence times are all close to the
optimum value for the inner-sphere contribution in the MRI T1-
shortening contrast agents as predicted by the
Solomon–Bloembergen–Morgan (SBM) theory.
Biodistribution studies and in vivo MRI. Most commercially
available Gd(III)-based MRI contrast agents are excreted rapidly
and exclusively through the renal pathway. One of the few
exceptions is an acyclic compound, Gd-EOB-DTPA, which has a
mixed clearance (50% renal, 50% biliary) and is used for imaging
of the liver and biliary system33. Gd-BOPTA and MS-325 have
predominantly renal elimination with <10% elimination through
the biliary system. The blood half-life of MS-325 is unusually long
owing to extensive serum albumin binding34, 35. We illustrated
with our studies that there is a signiﬁcant variation in the bio-
distribution proﬁles despite the small structural differences of the
chiral substituents (Supplementary Fig. 20). Gd biodistribution in
BALB/c mice was measured by ICP-MS at 5, 15, 30, 60, 180 and
360 min following injection. For the control/parent [GdDOTA]−,
we observed rapid elimination from the body via the kidneys as
expected36. Low levels of Gd(III) are present at 6 h post injection.
On the other hand, with the tetramethyl-substituted [GdL1]−,
near equal renal and hepatic clearance was observed. The tetra-
ethyl derivative [GdL2]− was mainly distributed in the liver but
its retention time in the liver was quite short; with negligible
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amounts of Gd(III) detected after 60 min from the ICP-MS stu-
dies. The speciﬁc and unusual localisation of [GdL2]− in the liver
makes it a potential hepatobiliary-speciﬁc MRI contrast agent.
Another interesting discovery was observed for [GdL5]−, where
the localisation proﬁle is mainly in the kidney and showed no
tendency of clearance after 6 h; thus, we hypothesise that the four
primary amino groups on the tetraaza ring may be recognised by
transporters in the cortex of the kidney. Moreover, it is important
and encouraging to note that minimal distribution in the brain
was observed for all the compounds, implying our contrast agents
are less toxic for clinical use.
Dynamic T1-weighted MR imaging at 4.7 tesla was performed
with C57/Bl6 mice before, during, and after 0.1 mmol per kg
injection of each compound (Fig. 7). For [GdL1]−, some
enhancement of the liver and gall bladder and enhancement of
the kidneys were observed as the contrast agent cleared, but 60
min post injection, the signal in the kidneys was similar to that at
baseline. For [GdL2B]−, profound enhancement of the liver and
gall bladder was observed, indicating efﬁcient uptake by
hepatocytes and elimination into the bile. Kidney enhancement
was also observed at early time points, but by 60 min the kidney
signal approached baseline. [GdL2A]− showed a very similar
behaviour to [GdL2B]− but not [GdL5]−, where very little
enhancement in the liver was observed.
In the kidneys, enhancement of the entire organ was observed
immediately after injection. Over time, the signal in the medulla
and renal pelvis approached baseline levels whereas the renal
cortex remained strongly enhanced, indicative of retention of the
compound [GdL5]−. Ex vivo biodistribution 2 h after injection
conﬁrmed the imaging ﬁndings with over 90 nmol Gd per g
kidney in the animal receiving [GdL5]−, compared to ≤20 nmol
Gd per g kidney with other contrast agents. The concentration of
Gd(III) in the gall bladder was extremely high (854 and 1066
nmol per g) for [GdL2A]− and [GdL2B]−, too (Supplementary
Table 2).
Radiometal labelling properties of L2. The labelling conditions
were ﬁrst evaluated with non radioactive ions. LCMS showed the
labelling of L2 with Cu(II) was fast at pH 6.0 at room tempera-
ture. The complexation of L2 and Cu(II) salt completed nearly
immediately after Cu(II) addition (Supplementary Fig. 21). Next
our ligand was tested with cold Lu(III) as 177Lu(III) is a good
radioisotope in radiotherapy. The labelling of L2 with Lu(III)
occurred at pH 7.0 at room temperature with the metal to ligand
ratio 1:1, while higher temperature is needed to get higher con-
version, which was monitored by LCMS (Supplementary Fig. 22
& 23).
Similar to cold labelling, instantaneous formation of 64CuL2
with the radioactive isotope 64Cu was observed using radio-HPLC
(pH 6.1, room temperature) with near quantitative radiochemical
yield. Radiochemical yield of 100 % was achieved after brief
heating at 40 °C for 30 min (Supplementary Fig. 24, Supplemen-
tary Table 3). In comparison, the radiochemical yield of
64CuDOTA under the same conditions was 89% upon mixing
at room temperature and 95% after heating at 40 °C for 30 min
(Supplementary Fig. 25).
In another radiolabeling study with 177Lu(III), it was found
that at least 80 °C was required to obtain [177LuL2]−. The
radiochemical yield of [177LuL2]− was near quantitative after
20–40 min at 95 °C (pH 5.0) with the highest radiochemical yield
over 95% (Fig. 8, Supplementary Fig. 26, Supplementary Table 4).
Compared to the formation of [177LuL2]− at the same
conditions, [177LuDOTA]− formation was slower with a radio-
chemical yield of 38% when heated at 95 °C (Fig. 8, Supplemen-
tary Fig. 27). Last but not least, [177LuL2]− can also be obtained
in pH 7.0 with an excellent radiochemical yield of 97% (95 °C, 20
min), which is not achievable at such mild pH conditions with
DOTA. All of these results indicate that L2 is a much better
ligand than DOTA for complexation of these two radioisotopes.
The stability of the complex is also a key parameter that needs
to be considered for a radiometal chelate19. The stability of
CuDOTA and CuL2 was compared by UV-Visible spectra. In 1N
HCl, CuDOTA showed rapid decomplexation, and the half-life of
the complex at these conditions was similar to the [GdDOTA]−
(<24 h) (Supplementary Fig. 28). The chiral version of CuL2
under the same conditions was much more stable. Because the
ionic radii of Lu(III) is very close to Yb(III), so we used the Yb
(III) as a surrogate to study the stability. Monitored by 1H NMR,
the complex of [YbDOTA]− in 1N DCl also decomplexed very
fast, but no obvious decomplexation was observed for the
complex of [YbL2]− (Supplementary Fig. 29). Additionally, we
examined in vitro serum stability of 64CuL2 at 37 °C. The
radiochemical purity of 64CuL2 decreased by less than 0.3 and
6.3% after 1 h and 24 h of incubation, respectively.
Discussion
The conformation of the Gd(III)-based complexes plays a sig-
niﬁcant role in the water exchange rate kex (kex= 1/τM)37. It has
been shown that the kex in the TSAP conﬁguration is 10–100
times faster than SAP, with the former useful as T1-shortening
contrast agents, and the latter desirable as paramagnetic chemical
exchange saturation contrast agents38, 39. Chiral DOTAs directly
inﬂuenced the conformation of their lanthanide complexes. The
ratio of formation of TSAP and the SAP isomers of these chiral
DOTA lanthanide complexes can be controlled by the choice of
functional groups used; as the bulkiness of these substituents
increases, the ratio of TSAP/SAP also increases; over 93% of
TSAP isomer of [LnL4]− was obtained when benzyl groups were
used. However, when four aminobutyl groups, which are more
ﬂexible and bulky, were introduced in [LnL5]−, ~100% of SAP
geometry was formed. High temperature 1H NMR experiments
TSAP/corner
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
TSAP/side
SAP/corner SAP/side
Fig. 6 Restricted isomerism of [GdL3]−. Four stereoisomers are possible for
[LnDOTA]−, but two of these structures are inaccessible with our system,
they are represented by the washed out structures. SAP/corner and TSAP/
side structures derived from the partial solved crystallographic data of
[GdL3]−; R represents the chiral substituent. Atom labels: C (grey), N
(blue) and O (red); H atoms omitted for clarity
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conﬁrmed that the ratios of isomers are stable and displayed no
obvious change over various temperatures. Studies with different
Ln(III) ions also revealed no change in the isomer ratios, dis-
missing the inﬂuence of metal ion size. Besides MRI, the control
of the stereoisomerism of the complexes is also very important for
some other applications: The stereoisomeric purity of chiral
luminescent lanthanide complexes are crucial for circularly
polarised luminescence (CPL) applications30, 40; Such rigid
paramagnetic complexes are also ideal pseudocontact shift tags
for proteins for NMR studies in solution and even in cells41, 42.
Gd-DOTMA and Gd-NB-DOTMA (S-RRRR), have relatively
fast water exchange rates in the TSAP geometry43, 44. However,
the study of Gd-NB-DOTMA found that a faster water exchange
rate gave a less efﬁciency than the slower one as the hydration
state (q r−6) is inversely proportional45. However, we found no
difference in relaxivities between the SAP and TSAP isomers in
our study. From the structures of the complexes, we noted that
the substitution on the α-position of acetate arms of the DOTA
complex may change the cavity of the chelator more than the
substitutions on the tetraaza ring; this is because the hydrophobic
bulky substituents near the coordinated water might affect the
interaction of the inner and outer sphere water molecules. While
for our chiral DOTA complexes, the coordination of the water
molecule in the ﬁrst sphere of the metal ions are retained like
their parent [GdDOTA]− complex, for the complexes with very-
short water residence time (s), like [GdL2B]−, the water residence
time is optimal for designing contrast agents with high relaxivity
at high magnetic ﬁelds (≥3 tesla)46–48.
The r1 values of [GdL1]−, [GdL2]− ([GdL2A]−, [GdL2B]−,
[Gd(R)L2A]−, [Gd(R)L2B]−) and [GdL5]− are largely invariant
in water at 1.4 T, 37 °C. Given the similar molecular weights and
similar chemical structures, one expects similar rotational corre-
lation times for these complexes. The similar relaxivities suggest
that the hydration number for these compounds is the same and
q= 1 by analogy to the Gd-DOTA-type complexes (Table 2). The
molecular weights of all the complexes are greater than
[GdDOTA]−, which results in modestly higher relaxivities. We
also measured relaxivities in 4.5% (w/v) human serum albumin
(HSA) solution and in human plasma. The relaxivities are slightly
elevated in these media but not more than [GdDOTA]−, sug-
gesting little to no plasma protein binding. The favourable
properties of these Gd complexes, such as fast and tunable water
exchange kinetics, kinetic inertness with respect to Gd release,
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Fig. 7MR imaging in mice. Dynamic T1-weighted MR images at 4.7 tesla in C57/Bl6 mice before, after 0.1 mmol per kg injection of [GdL1]−, [GdL2B]− and
[GdL5]−. Axial images of the liver (L) and gall bladder (arrow) coronal images of the kidneys highlighting the differences in elimination route and organ
enhancement among the complexes
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Fig. 8 Radiolabeling yields of 177Lu complexes. A graph of the radiolabeling
yields of L2 and DOTA with 177Lu(III) against time at 95 °C in pH 5.0 buffer,
showing that L2 is a better chelator for 177Lu(III)
Table 1 Coordination and ﬁtting parameters 17O relaxation proﬁles
[GdL1]− [GdL2A]− [GdL2B]− [Gd(R)L2A]− [Gd(R)L2B]− [GdL5]− [GdDOTA]−43, 59 Gd-
DOTMA43
Gd-NB-DOTA60 Gd-NB-
DOTMA
(S-SSSS)44
Gd-NB-
DOTMA(S-
RRR)44
Coordination Mix SAP TSAP SAP TSAP SAP SAP TSAP SAP TSAP Mix SAP TSAP
τM
310K (ns) 13 ± 0.4 6.6 ± 0.4 1.1 ± 0.1 8.1 ± 0.4 2.9 ± 0.1 16 ± 0.8 141 27 156 26 111 77 9.4
ΔH‡ (kJ mol-1) 16 ± 1.4 43 ± 2.0 29 ±3 .2 33 ± 2.1 12 ± 1.7 18 ± 2.5 58.1 ± 2.5 41.9 ± 3.1 53.4 ± 2.9 40.3 ± 2.2 35.5 26.4 27.7
The mean residence time of the water co-ligand at 310 K (τM310K) and enthalpy change of activation of water exchange (ΔH‡) for Gd(III) complexes. Each measurement was repeated three times and an
average value is given. Error values refer to statistical data ﬁtting analysis (n= 3; s.e.m.)
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and ease of derivatization indicate that the chiral DOTA tech-
nology will serve as a very-useful platform in the design of high
relaxivity and targeted MRI contrast agents49–51. For example,
our chiral cyclen platform enables four inert substituents on the
other side of the tetraaza plane to be potentially conjugated with
four binding moieties to minimise the rotation of the whole
molecule, therefore enabling maximum relaxivity enhancement.
Such a strategy to achieve multilocus binding has been proven
successful in the literature52–54.
Our chiral modiﬁcations of the ring have forced the four
acetate groups to form a natural cavity, which enables better
chelation. This is in contrast to the normal DOTA chelate in
which, with only four acetate groups, the pendant arms form a
more disordered structure, thus having a lower entropy in the
process of sequestering the metal ions; hence, we predict that
leads to a much more rapid complexation rate. This resonates
with our hypothesis that the formation of natural cavity in our
chiral DOTA ligands from having four extra substituents on the
same side simpliﬁes the structural preorganisation step in the
complexation leading towards fast complexation.
In summary, we demonstrated the synthesis of a series of chiral
DOTA chelators with four substituents symmetrically arranged
around the cyclen ring. Our chiral DOTA Gd(III) complexes
display faster water exchange kinetics (τM 1.1–16 ns at 310K) than
[GdDOTA]− and are stable at harsh temperature and extreme pH
environments. To the best of our knowledge, only one lanthanide
complex has been published with comparable kinetic inertness
thus far55.These complexes also have unique biodistribution
proﬁles for organ-speciﬁc applications, such as the hepatobiliary-
speciﬁc [GdL2]− and show near-zero distribution in mice brains.
The work shows that our chiral DOTA chelators, in terms of
structural rigidity, inertness, water exchange kinetics and fast
radiolabelling properties have clearly transcended the DOTA
ligand, and show promise as an ideal platform for the develop-
ment of safer and more efﬁcient agents for potential applications
as protein tags for NMR and electron paramagnetic resonance
(EPR) studies, highly efﬁcient MRI contrast agents and radio-
metal chelators for PET or SPECT imaging.
Methods
General materials and methods. Unless otherwise noted, all chemicals were of
reagent-grade and were purchased from Sigma-Aldrich or Acros Organics and
used without further puriﬁcation, (2 S)-1-Benzyl-2-ethylaziridine, (S)-1-benzyl-2-
isobutylaziridine and (S)-1,2-dibenzylaziridine were ordered from Beijing Peri-
dachem Co., Ltd. 1H and 13C NMR spectra were recorded on a Bruker Ultrashield
400 Plus NMR spectrometer (at 400MHz and 100MHz, respectively) or a Bruker
Ultrashield 600 Plus NMR spectrometer (at 600MHz and 150MHz, respectively).
Unless otherwise speciﬁed, chemical shifts δ were expressed in parts per million
(ppm) based on the residual solvent signal in DMSO-d6 (δ 2.50 ppm), D2O (δ 4.79
ppm), CD3OD (δ 3.31 ppm) or tetramethylsilane in CDCl3 (δ 0.00 ppm), and
coupling constants J are given in Hz. Coupling patterns are abbreviated as s
(singlet), d (doublet), t (triplet), q (quartet), dd (doublets of double), ddd (doublets
of doublets of doublet), dt (doublets of triple), dtd (doublets of triplets of doublet),
dq (doublets of quartet), and m (multiplet). Liquid chromatography-mass spec-
trometry was performed using an Agilent 1100 series apparatus with an LC/MSD
trap and Daly conversion dynode detector with UV detection at 220, 254, and 280
nm. The method used on this system is as follows: Restek ultraaqueous C18 col-
umn (100 × 4.6 mm); eluent A: 10 mM ammonium acetate in water, B: 90% acet-
onitrile/10% 10 mM ammonium acetate in water; gradient: 5% B was held for 2
min before increasing the fraction of B to 50% over 10 min. The column was
washed with 95% B for 2 min and then ramped to 5% B. The system was re-
equilibrated at 5% B for 2 min. Reverse-phase semi-preparative puriﬁcation was
performed on either of these two systems. System A: Rainin Dynamax HPLC
system with UV detection from 220 to 280 nm using a Restek Ultraaqueous C18
Column (250 × 10 mm). The mobile phase A was water with 10 mM ammonium
acetate added; mobile phase B was 90% acetonitrile/10% water with 10 mM
ammonium acetate added. The method used for puriﬁcation is as follows: starting
from 95% A/5% B, the fraction of B increased to 50% over 23 min. The column was
washed with 95% B for 2 min and then ramped to 5% B. The system was re-
equilibrated at 5% B for 3 min. System B: Waters HPLC system with UV detection
from 210 to 280 nm using a Waters C18 Column (250 × 19mm). The mobile phase
A was water with 10 mM ammonium formate added; mobile phase B was 90%
acetonitrile/10% water with 10 mM ammonium formate added; The method used
for puriﬁcation is as follows: starting from 95% A/5% B, the fraction of B increased
to 50% over 23 min. The column was washed with 95% B for 2 min and then
ramped to 5% B. The system was re-equilibrated at 5% B for 3 min. Ultra-
performance liquid chromatography-high resolution mass spectrometry was per-
formed using an Agilent 1260 Inﬁnity Series apparatus with Agilent 6540 UHD
Accurate-Mass Q-TOF LC/MS detection in the range of 100–3000. The method
used on this system is as follows: Agilent Eclipse Plus C18 RRHD 1.8 µm column
(50 × 2.1 mm), eluent A: water with 0.1% formic acid, eluent B: acetonitrile. Radio-
HPLC was performed using an Agilent 1260 Inﬁnity Series apparatus with Phe-
nomenex Luna 5 u C18(2) 100 Å (150 × 4.6 mm); eluent A: water with 0.1% tri-
ﬂuoroacetic acid, eluent B: acetonitrile with 0.1% triﬂuoroacetic acid.
Syntheses. All the compounds were fully characterized. Experiment details and
characterisations are given in Supplementary Methods (NMR spectra were shown
in Supplementary Figs. 30–82, high resolution ESI-MS of complexes were shown in
Supplementary Figs. 83–92).
Relaxivity and water exchange rate measurements. Relaxivity measurements
were performed on a Bruker mq60 Minispec at 1.41T and 37 °C. Longitudinal (T1)
relaxation times were measured using an inversion recovery experiment with 10
inversion times of duration ranging between 0.05 × T1 and 5 × T1. Transverse (T2)
relaxation times were measured using a CPMG pulse sequence. Relaxivity (r1, r2)
was determined from the slope of a plot of 1/T1,2 vs [Gd] for at least 4 con-
centrations of Gd(III) (data shown in Supplementary Figs. 93–110). The T2
relaxation times of 17O at 11.7T were estimated from the full-width at half-height
of the H217O resonance at temperatures ranging from 278 to 368K. Reduced
relaxation rates (1/T2r) were calculated by taking the difference of 1/T2 measured in
the presence and absence of Gd(III) and dividing by the mole fraction of coordi-
nated water molecules, assuming q= 1. This data was plotted vs reciprocal tem-
perature and ﬁt to a 4-parameter model dependent on water exchange and
electronic relaxation as described previously56. However, at the high magnetic ﬁeld
used, and because of the very-fast water exchange rates observed, there was neg-
ligible contribution of T1e, and the data were reﬁt to a two-parameter model using
the water exchange rate at 310K (τM) and enthalpy of activation for water exchange
(ΔH‡) as adjustable parameters. The Gd-O hyperﬁne coupling constant, A/ħ, was
assumed to be -3.8 × 106 rad s−1 57, 58. Samples were prepared in neat H2O
adjusted and enriched with a small amount of H217O.
Gd quantiﬁcation. Gd concentrations were determined using an Agilent 8800-
QQQ ICP-MS system. All samples were diluted with 0.1% Triton X-100 in 5%
nitric acid. Lutetium internal standard was steadily introduced to the ICP-MS from
an external source during the analysis. A linear calibration curve for each metal
ranging from 0.1 ppb to 200 ppb was generated daily for the quantiﬁcation.
Protein binding. Measurements were performed on a series of solutions ranging
between 15-400 µM Gd complex in either 4.5% wt/v (HSA) or human blood
plasma. A volume of 500 µL of each solution was placed within a Millipore Ultra
Free MC 30 kDa cutoff ﬁltration vessel and 20 µL of the solution was forced
through the ﬁlter by centrifugation. Gd content in each unﬁltered solution and
ﬁltrate were quantiﬁed by ICP-MS. The percentage of each complex bound to
albumin was determined from the difference in Gd concentrations between
unﬁltered solution and ﬁltrate.
In Vivo MR imaging. Imaging was performed at 4.7T using a small-bore animal
scanner (Bruker Biospec). Pilot dynamic MRI studies were performed with
[GdL1]−, [GdL2A]−, [GdL2B]− and [GdL5]−; n= 1 per compound. Six to eight
weeks male C57/Bl6 mice were anaesthetised with isoﬂurane (1%–2%) and placed
in a specially designed cradle with body temperature maintained at 37 °C. The tail
Table 2 Relaxivities of Gd complexes
Water (1.4T) 4.5% w/v HSA
(1.4T)
Human Plasma
(1.4T)
Sample r1 r2 r1 r2 r1 r2
[GdL1]- 4.1 5.1 4.5 5.3 4.6 5.5
[GdL2A]- 4.2 5.5 4.7 5.5 4.7 5.6
[GdL2B]- 3.9 4.9 4.8 6.0 4.9 6.1
[Gd(R)L2A]- 3.9 5.0 4.5 4.9 4.6 4.8
[Gd(R)L2B]- 3.9 4.9 4.8 6.1 4.9 6.1
[GdL5]- 4.1 5.9 5.1 6.3 5.1 6.3
[GdDOTA]- 3.2 3.2 4.1 4.8 4.0 4.0
Summary of relaxivities of [GdL1]-, [GdL2A]-, [GdL2B]-, [Gd(R)L2A]-, [Gd(R)L2A]-, [GdL5]-
and [GdDOTA]- in water, HSA and human plasma.
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vein was catherised for intravenous delivery of the contrast agent while the animal
was positioned in the scanner. A pneumatic pillow was placed on the mouse to
enable respiratory monitoring (SA Instruments), and the animal’s body tempera-
ture was maintained with warm air. The imaging protocol utilised a three-
dimensional fast low angle shot (3D FLASH) with a 12 °C ﬂip angle, 9.00 ms
repetition rate, 2.39 ms echo time, 4.8 cm × 2.4 cm × 2.4 cm ﬁeld of view with a 0.3
mm isotropic resolution. Images were acquired with either 2 or 8 averages giving
an acquisition time of 2 min or 8 min, respectively. Baseline images were acquired
with both 2 and 8 averages, then the Gd complex (0.1 mmol per kg) was injected
intravenously and the sequence with 2 averages was repeated for a period of 10 min
to monitor blood clearance. At 10, 30, 45, 60, 75 and 90 min after probe injection,
the sequence with 8 averages was repeated to monitor the clearance of contrast
from the liver and kidneys. After imaging was performed, the mouse was removed
from the scanner and euthanized at 2 h post injection and the tissues were har-
vested for Gd quantiﬁcation by ICP-MS.
Gd complexes biodistribution studies. Complexes [GdL1]−, [GdL2]− and
[GdL5]− were prepared by dissolving in saline solution, while [GdDOTA]−
(Dotarem) was diluted in saline solution. Eight-week-old male BALB/c mice
(purchased from BioLASCO, Taiwan) each weighing approximately 25 g were
administered with a single dose of 0.025 mmol/kg compound ([GdL1]−, [GdL2]−,
[GdDOTA]− and [GdL5]−; 3 mice per compound per time point) in a 100 μl
volume via lateral tail vein injection. The mice were then euthanized, and their
blood collected by cardiac puncture at each time point (5, 15, 30, 60, 180 or 360
min post injection). A control group of 4 mice was treated with saline and killed at
time point 0. The liver, lung, heart, kidneys, spleen and brain were removed from
the animals and weighed. Gd content in tissue and blood samples was quantiﬁed
via ICP-MS analysis. All experiments were performed in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and approved by the Institu-
tional Animal Care and Use Committee of Massachusetts General Hospital or by
the Department of Health of the Hong Kong Government and the Animal Subjects
Ethics Sub-Committee of Hong Kong Polytechnic University.
64Cu labelling. Vials containing 5 nmol of L2 or DOTA (Macrocyclics, Plano, TX)
[2.5 μL of 2 mM solutions in water], and 50 μL of 0.5 M NH4OAc buffer (pH 6.05)
were mixed with 1.5 µL of 64CuCl2 solution (1.0 mCi, from Washington Uni-
versity). The reaction solutions were mixed and brieﬂy centrifuged. A small aliquot
was taken immediately and diluted with 50 µL of 0.5 M NH4OAc (pH 6.05) and
analysed by radio-HPLC. The mixtures were then heated to 40 °C for 20 min. A
small aliquot was taken and analysed by radio-HPLC to quantify radiochemical
yields.
177Lu labelling. Vials containing 4 nmol of L2 (2 μL of 2 mM solution in water),
and 100 μL of 0.5 M NH4OAc buffer (pH range from 4.0 to 7.0) were mixed with
0.2 μL of 177LuCl3 (in 0.1 M HCl; MURR, Columbia, MO). The reaction mixtures
were mixed, brieﬂy centrifuged and left to react at speciﬁc temperatures. A small
aliquot of the crude labelling mixtures was taken at each time point and analysed
by radio-HPLC to quantify radiochemical yields.
Data availability. The X-ray crystallographic data has been deposited at the
Cambridge Crystallographic Data Centre with deposition number (CCDC
1517731), (CCDC 1517730), (CCDC 1517732), (CCDC 1517729), (CCDC
1445318) and (CCDC 1497014). This data can be obtained free of charge via www.
ccdc.cam.ac.uk/conts/retrieving. html. All other data supporting the ﬁnding in this
study are available within the article and its Supplementary Information, as well as
from the authors upon reasonable request.
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